- 著者
- Ryuichiro TANAKA Hiroo TAKAYAMA Masami MOROTOMI Toshikata KUROSHIMA Sadao UEYAMA Keisuke MATSUMOTO Akio KURODA Masahiko MUTAI
- 出版者
- Japan Bifidus Foundation
- 雑誌
- Bifidobacteria and Microflora (ISSN:02869306)
- 巻号頁・発行日
- vol.2, no.1, pp.17-24, 1983 (Released:2011-02-23)
- 参考文献数
- 25
- 被引用文献数
- 130 184
We studied the effects of administration of TOS, a new growth factor derived from lactose for Bifidobacterium, and Bifidobacterium breve 4006 on the fecal flora of normal subjects. All of the Bifidobacterium species tested, eight reference strains and B. breve 4006 were capable of fermenting TOS in vitro, while others, 2 Bacteroides strains and 4 Lactobacillus and Enterobacteriaceae strains, showed an appreciable growth among 55 cultures tested. It was evident that TOS is not intestinally absorbed by the recipient subjects, from hydrogen breath test. In vivo, TOS (3g or 10g/day) was observed to promote the growth of both administered B. breve 4006 and resident Bifidobacterium strains. Simultaneous administration of B. breve 4006 and TOS caused the suppression of gram negative anaerobes and aerobes, Bacteroidaceae and Enterobacteriaceae, and the reduction of fecal ammonia and urinary indican excretion. It is concluded that TOS is a typical bifidus factor.
1 0 0 0 OA ANTITUMOR ACTIVITY OF A NEW CAMPTOTHECIN DERIVATIVE, SN-22, AGAINST VARIOUS MURINE TUMORS
- 著者
- TAKEHIKO KUNIMOTO KAZUO NITTA TOMIKO TANAKA NOBUAKI UEHARA HIROYASU BABA MIEKO TAKEUCHI TERUO YOKOKURA SEIGO SAWADA TADASHI MIYASAKA MASAHIKO MUTAI
- 出版者
- The Pharmaceutical Society of Japan
- 雑誌
- Journal of Pharmacobio-Dynamics (ISSN:0386846X)
- 巻号頁・発行日
- vol.10, no.3, pp.148-151, 1987 (Released:2008-02-19)
- 参考文献数
- 7
- 被引用文献数
- 7 15
The antitumor activity of a new camptothecin derivative, SN-22, was evaluated by using various murine tumors. SN-22 showed strong activity against the ascites tumors Ehrlich carcinoma, MM46, CCM, L1210, L5178Y, P388, Meth A, and B16 melanoma. In particular, the maximum increase in life span values for Ehrlich, MM46 and CCM were as high as 253-606% and many mice were cured of these tumors. The effect of SN-22 against solid tumors was also determined. The inhibition ratios were higher than 70% for MM46 and L5178Y. The LD50 of SN-22 in ICR mice was about 1.5 times that of the parent camptothecin.